0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV81.92%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma22.12Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Omeros Stock Discussion
What the hell???!!!
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
Omeros announced that its MASP-3 inhibitor zaltenibart (OMS906) received rare pediatric disease designation from the FDA for treating C3 glomerulopathy (C3G), an ultra-rare renal disorder affecting children and young adults. The company plans to initiate Phase 3 trials for C3G in 2024. Zaltenibart is also being developed for paroxysmal nocturnal hemoglob...
No comment yet